What's in Staci Gruber, Ph.D.'s pipeline?

Staci Gruber, Ph.D. has 2 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Staci Gruber, Ph.D.'s portfolio?

Top competitors by shared drug class: Gold Coast Hospital and Health Service, Hôpital le Vinatier, Montefiore Medical Center, OMNI Medical Services, LLC, Stero Biotechs Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/staci-gruber-ph-d.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Staci Gruber, Ph.D. — Portfolio Competitive Intelligence Brief

Staci Gruber, Ph.D. pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Gold Coast Hospital and Health Service · 1 shared drug class
Hôpital le Vinatier · 1 shared drug class
Montefiore Medical Center · 1 shared drug class
OMNI Medical Services, LLC · 1 shared drug class
Stero Biotechs Ltd. · 1 shared drug class
University of California, San Diego · 1 shared drug class
University of Connecticut · 1 shared drug class
Wayne State University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Staci Gruber, Ph.D.:

Cite this brief

Drug Landscape (2026). Staci Gruber, Ph.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/staci-gruber-ph-d. Accessed 2026-05-16.